US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

27.93

+2.027.78%

Volume:525.82K

Turnover:13.96M

Market Cap:1.60B

PE:-12.00

High:28.05

Open:25.50

Low:25.29

Close:25.91

Loading ...

Overview Company News Filings

Structure Therapeutics Inc. FY Net Income USD -122.526 Million

THOMSON REUTERS

Structure Therapeutics Inc - Expects Cash to Fund Operations Through 2027

THOMSON REUTERS

Structure Therapeutics Inc. FY Income From Operations USD -158.228 Million

THOMSON REUTERS

Press Release: Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement

MT Newswires Live

Exicure announces purchase agreement with GPCR Therapeutics

Press Release: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Structure Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $50

THOMSON REUTERS

Structure Therapeutics initiated with a Buy at Stifel

Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

BUZZ-Viking set to double in 'challenging' year for obesity drug developers

Exicure to Acquire GPCR Therapeutics' US Unit

MT Newswires Live

Exicure signs MOU with GPCR Therapeutics

Press Release: Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion

Shares of Viking Therapeutics up 4.2%, Amgen up 1%

THOMSON REUTERS

Weight Loss Drug Developers Rise After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected

THOMSON REUTERS

BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study

Weight Loss Drug Developers Rise Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GPCR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":27.925,"timestamp":1746025060671,"preClose":25.91,"halted":0,"volume":525816,"delay":0,"floatShares":49653148,"shares":57342847,"eps":-2.327592,"marketStatus":"Trading","change":2.015,"latestTime":"04-30 10:57:48 EDT","open":25.5,"high":28.05,"low":25.29,"amount":13962470.740559999,"amplitude":0.106523,"askPrice":28,"askSize":6,"bidPrice":27.8,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-2.327592,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":25.91,"preHourTrading":{"tag":"盘前","latestPrice":25.5,"preClose":25.91,"latestTime":"09:29 EDT","volume":3574,"amount":92260.372532,"timestamp":1746019772578},"postHourTrading":{"tag":"盘后","latestPrice":24.62,"preClose":25.91,"latestTime":"19:00 EDT","volume":8732,"amount":226000.46,"timestamp":1745967646596},"volumeRatio":2.785677,"impliedVol":0.8837,"impliedVolPercentile":0.696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":49653148,"roa":"-14.28%","roe":"-18.60%","lyrEps":-2.327592,"volumeRatio":2.785677,"shares":57342847,"dividePrice":0,"high":28.05,"amplitude":0.106523,"preClose":25.91,"low":25.29,"week52Low":13.22,"pbRate":"1.85","week52High":62.74,"institutionHeld":0,"latestPrice":27.925,"committee":0.538462,"eps":-2.327592,"divideRate":0,"volume":525816,"delay":0,"ttmEps":-2.327592,"open":25.5,"prevYearClose":27.12,"prevWeekClose":23.74,"prevMonthClose":17.31,"prevQuarterClose":17.31,"fiveDayClose":23.32,"twentyDayClose":15.79,"sixtyDayClose":28.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514998330","title":"Structure Therapeutics Inc. FY Net Income USD -122.526 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514998330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514998330?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2514355504","title":"Structure Therapeutics Inc - Expects Cash to Fund Operations Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355504?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2514233054","title":"Structure Therapeutics Inc. FY Income From Operations USD -158.228 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233054?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2514233058","title":"Press Release: Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233058?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"Aleniglipron  ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025. Oral small molecule amylin receptor agonist  Investigational New Drug -enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025. Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million. SAN FRANCISCO, Feb. 27, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","BK4139","LENZ","GPCR"],"gpt_icon":1},{"id":"2507062300","title":"Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2507062300","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507062300?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:30","pubTimestamp":1738243800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Jan. 30, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/structure-therapeutics-participate-multiple-upcoming-133000019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GPCR","HCSG","BK4139","BK4007","BK4137","BK4599","LENZ"],"gpt_icon":0},{"id":"2505402066","title":"Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505402066","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505402066?lang=en_us&edition=fundamental","pubTime":"2025-01-23 16:52","pubTimestamp":1737622351,"startTime":"0","endTime":"0","summary":"Exicure  said late Wednesday it has agreed to acquire all shares of GPCR Therapeutics USA, a subsidiary of GPCR Therapeutics, a Korean corporation.In connection with the deal, Exicure and GPCR made a licensing and collaboration agreement to further develop and commercialize certain GPCR technologies, the company said.Financial terms were not disclosed.Under the agreement, Exicure is to pay GPCR milestone payments upon reaching specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as a recurring royalty payment based on at least 10% of net sales, the company said.Shares of Exicure were up more than 46% in Wednesday's after-hours activity.Price: 15.21, Change: +4.84, Percent Change: +46.67","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","GPCR","XCUR","BK4599","BK4139"],"gpt_icon":1},{"id":"2505706822","title":"Exicure announces purchase agreement with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706822?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:05","pubTimestamp":1737579939,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) “announced that on January 19, 2025, Exicure Inc. entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-announces-purchase-agreement-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-announces-purchase-agreement-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","BK4139","BK4007","GPCR","XCUR"],"gpt_icon":0},{"id":"2505705211","title":"Press Release: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705211","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705211?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:01","pubTimestamp":1737579660,"startTime":"0","endTime":"0","summary":"Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc.  entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation , pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation . The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately prior to closing under the Share Purchase Agreement, a wholly owned subsidiary of GPCR.In December of last year, GPCR USA presented results at the American Society of Hematology conference, indicating that inhibiting both CXCR4 and ADRB2  resulted in a more than tenfold increase in the anti-cancer efficacy of the AML chemotherapy drug cytarabine. Notably, they reported high response rates and excellent safety profiles in patients receiving the new blood cancer drug daratumumab. Dr. Caderelli stated, \"After completing patient treatment, we","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","HSCT","XCUR","CTO","BK4160","BK4599","BK4139"],"gpt_icon":1},{"id":"2501074060","title":"Structure Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2501074060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501074060?lang=en_us&edition=fundamental","pubTime":"2025-01-08 19:29","pubTimestamp":1736335776,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O4193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2501758537","title":"Structure Therapeutics initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2501758537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501758537?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:21","pubTimestamp":1736284876,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $50 price target Structure aims to expand the reach of metabolic t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR","BK4599","BK4127","SF","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2501238174","title":"Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501238174","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501238174?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164800,"startTime":"0","endTime":"0","summary":"Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company's finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar's Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4555","TM","GPCR","SEPN","BK4585","BK4007","03160","BK4588","BK4099"],"gpt_icon":0},{"id":"2500617073","title":"BUZZ-Viking set to double in 'challenging' year for obesity drug developers","url":"https://stock-news.laohu8.com/highlight/detail?id=2500617073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500617073?lang=en_us&edition=fundamental","pubTime":"2025-01-01 00:58","pubTimestamp":1735664317,"startTime":"0","endTime":"0","summary":"BUZZ-Viking set to double in 'challenging' year for obesity drug developers ** Viking Therapeutics' VKTX.O shares have more than doubled this year, on track for a third successive year of gains** Shares of other smaller obesity drug developers such as Structure Therapeutics GPCR.O, Altimmune ALT.O and Amgen AMGN.O are set to end the year in the red ** BMO Capital analysts termed 2024 a \"challenging year for obesity trade\" - as investors previously got significant returns by banking on names such as VKTX, GPCR and ALT that were entering the weight-loss space** Brokerage says that while obesity remains an \"enormous\" long-term revenue opportunity, investors have become more selective and focus on \"clearly differentiated\" products ** In November, VKTX reported promising data of its oral drug candidate, VK2735, but analysts raised concerns about its ability to mass produce the treatment ** Data from Amgen's closely watched weight-loss drug MariTide failed to impress investors — and wiped of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nL4N3NW0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4599","LU2242652126.USD","LU1057294990.SGD","BK4534","LU0122379950.USD","LU2112291526.USD","BK4566","BK4585","LU0058720904.USD","ALT","BK4007","VKTX","LU0289739699.SGD","LU1878469433.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4533","GPCR","BK4588","LU1023059063.AUD","LU1983299246.USD","LU0868494617.USD","IE00B4R5TH58.HKD","IE0009355771.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","BK4139","IE0002141913.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4581","LU1571399168.USD","AMGN"],"gpt_icon":0},{"id":"2494387996","title":"Exicure to Acquire GPCR Therapeutics' US Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2494387996","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494387996?lang=en_us&edition=fundamental","pubTime":"2024-12-27 16:51","pubTimestamp":1735289493,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) said late Thursday it signed a memorandum of understanding with GPCR Therapeutics for the acquisition of the South Korean company's US subsidiary, GPCR USA, to advance its growth as a c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4599","XCUR","BK4139","BK4007","GPCR"],"gpt_icon":0},{"id":"2494843517","title":"Exicure signs MOU with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2494843517","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494843517?lang=en_us&edition=fundamental","pubTime":"2024-12-27 09:25","pubTimestamp":1735262745,"startTime":"0","endTime":"0","summary":"The company states: “Exicure (XCUR) has announced the signing of a Memorandum of Understanding, MOU, with GPCR Therapeutics on December 24, 2024, a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-signs-mou-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-signs-mou-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4599","XCUR","GPCR","BK4007"],"gpt_icon":0},{"id":"2494810219","title":"Press Release: Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2494810219","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494810219?lang=en_us&edition=fundamental","pubTime":"2024-12-27 09:08","pubTimestamp":1735261680,"startTime":"0","endTime":"0","summary":"Exicure, Inc. , has announced the signing of a Memorandum of Understanding  with GPCR Therapeutics, Inc.  on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics' ongoing drug development pipelines. Through this acquisition, Exicure plans to secure key technical personnel by purchasing all shares of GPCR USA held by GPCR Therapeutics. Following this, Exicure intends to receive technology transfer for GPCR Therapeutics' CXCR4 inhibitor, which is currently in Phase 2 clinical trials with the FDA, along with its related patents and intellectual property . By acquiring excellent research personnel and clinical pipelines, Exicure aims to advance as a clinical-stage biotech company. GPCR Therapeutics plans to successfully finalize ongoing clinical trials involving stem cell mobilizers  targeting multiple myeloma patients and prepare for clinical studies related to acute myeloid ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IP","BK4135","ASH","XCUR","BK4139","GPCR","BK4007","BK4599","LU2463526074.USD","BK4109","SCM","BK4136","BK4588"],"gpt_icon":0},{"id":"2492442333","title":"FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2492442333","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492442333?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:59","pubTimestamp":1734706749,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap market worth $150 billionUpdates with latest trial details on Novo, Lilly, Amgen, Viking, and Zealand Pharma; adds Merck and AstraZeneca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4N3NL0OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089283258.USD","AMGN","LU0061475181.USD","BK4585","LU2361044949.HKD","LU2242646821.SGD","SG9999015341.SGD","BK4196","GPCR","03692","LU0079474960.USD","LU1323610961.USD","LU1814569148.SGD","LU0820561818.USD","LU1084165304.USD","LU0823399737.USD","LU0417517546.SGD","LU0456855351.SGD","BK4530","LU0882574055.USD","LU1366192091.USD","LU2089984988.USD","PFE","LU1119994496.HKD","LU1064131342.USD","CTLT","LU0128525689.USD","SG9999014898.SGD","03165","LU0997586432.USD","LU0058720904.USD","LU0792757196.USD","OPK","LU2361045086.USD","AZN.UK","MRK","ALT","LU0203202063.USD","LU2237443622.USD","SGXZ51526630.SGD","LU0385154629.USD","LU2242652126.USD","SG9999018865.SGD","SGXZ81514606.USD","SG9999014880.SGD","LU1712237335.SGD","VKTX","SG9999015358.SGD","LLY","SGXZ99366536.SGD"],"gpt_icon":1},{"id":"2492441492","title":"Shares of Viking Therapeutics up 4.2%, Amgen up 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492441492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492441492?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:32","pubTimestamp":1734705149,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NL0NT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4533","SG9999001440.SGD","LU0320765992.SGD","LU0289739699.SGD","BK4581","BK4599","LU1057294990.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU1061106388.HKD","ALT","LU0109394709.USD","VKTX","IE00B4R5TH58.HKD","LU1983299246.USD","LU1023059063.AUD","BK4007","IE00BJJMRZ35.SGD","AMGN","LU0058720904.USD","LU2112291526.USD","IE00BJT1NW94.SGD","LU2242652126.USD","GPCR","LU0868494617.USD","BK4588","BK4566","LU0889565916.HKD","LU1571399168.USD","LU0122379950.USD","BK4534","IE0002141913.USD","BK4139","BK4585","LU1878469433.USD"],"gpt_icon":0},{"id":"2492419874","title":"Weight Loss Drug Developers Rise After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2492419874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492419874?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:32","pubTimestamp":1734705149,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a469344a0fb92d1bb998ed1b12947db3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NL0NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","AMGN","LU0122379950.USD","BK4139","SG9999001440.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1023059063.AUD","LU0868494617.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","GPCR","BK4533","BK4581","IE0009355771.USD","LU1571399168.USD","LU0889565916.HKD","ALT","BK4585","IE00BJJMRZ35.SGD","LU1061106388.HKD","BK4007","LU0320765992.SGD","LU1878469433.USD","BK4599","VKTX","LU2242652126.USD","BK4534","LU2112291526.USD","BK4588","IE00BJT1NW94.SGD","BK4566","LU0109394709.USD","LU2242646821.SGD","LU1983299246.USD","IE0002141913.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2492541972","title":"BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2492541972","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492541972?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:40","pubTimestamp":1734694854,"startTime":"0","endTime":"0","summary":"BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study** Shares of some weight-loss drug developers rise premarket, after Novo Nordisk's NOVOb.CO experimental next-generation obesity drug achieves lower weight loss than expected in a late-stage trial** Novo says its drug, CagriSema, helped overweight patients cut their weight by 22.7%, below the 25% it had expected** Shares of Viking Therapeutics VKTX.O up 11.5%, Structure Therapeutics GPCR.O up 7.1%, Altimmune ALT.O up 2.2% and Amgen AMGN.O climb 5.5% before the bell** U.S.-listed shares of Novo fall 22.4%, while rival Eli Lilly LLY.N climbs 10%** Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market** Lilly's obesity drug, sold as Zepbound in the U.S., led to an average weight loss of nearly 23% in clinical trials** Up to last close, AMGN down 9.3%, GPCR down 26.5% and ALT dow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4N3NL0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LLY","ALT","GPCR","VKTX"],"gpt_icon":1},{"id":"2492415996","title":"Weight Loss Drug Developers Rise Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2492415996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492415996?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:03","pubTimestamp":1734692639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NL0CN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0471298694.HKD","LU0094547139.USD","LU0417517546.SGD","SG9999014914.USD","ALT","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","LU0672654240.SGD","LU1023059063.AUD","SG9999014880.SGD","GPCR","LU0289739699.SGD","LU0823416689.USD","LU1127390331.HKD","IE0004445239.USD","GB00BDT5M118.USD","LU2491050071.SGD","LU2264538146.SGD","SG9999015978.USD","LU0882574139.USD","LU0203202063.USD","LU1291159041.SGD","IE0002141913.USD","LU0640476718.USD","LU0466842654.USD","LU0320765059.SGD","LU0203201768.USD","SGXZ81514606.USD","LLY","LU1983299246.USD","SG9999015986.USD","LU0354030438.USD","IE00B2B36J28.USD","BK4516","SG9999015945.SGD","BK4599","LU2237438978.USD","LU2106854487.HKD","LU1868837300.USD","SG9999018865.SGD","LU1989771016.USD","LU2461242641.AUD","LU2023250504.SGD","VKTX","LU0006306889.USD","LU0256863902.USD","LU2361045086.USD","LU1974910355.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.6154,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6154,"analysts":13,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-04-29","current":-11.054291,"percent":0.925512,"low":-50.180001,"twenty":-25.220395,"median":-20.941421,"eighty":-16.40274,"high":-6.622278,"avg":-21.570752,"sd":7.887014,"marketCap":1354438046},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-04-29","current":-11.054291,"twenty":-25.220395,"median":-20.941421,"eighty":-16.40274,"marketCap":1354438046}],"updateTime":1746019004291}}}